Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by Quantbot Technologies LP

Quantbot Technologies LP reduced its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 20.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,620 shares of the company’s stock after selling 3,832 shares during the period. Quantbot Technologies LP’s holdings in Vir Biotechnology were worth $107,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Intech Investment Management LLC purchased a new position in Vir Biotechnology in the third quarter valued at about $191,000. Charles Schwab Investment Management Inc. raised its position in shares of Vir Biotechnology by 13.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,134,276 shares of the company’s stock valued at $8,496,000 after purchasing an additional 136,087 shares in the last quarter. Dynamic Technology Lab Private Ltd boosted its stake in shares of Vir Biotechnology by 77.2% during the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 31,900 shares of the company’s stock valued at $239,000 after buying an additional 13,893 shares during the last quarter. Public Sector Pension Investment Board grew its position in shares of Vir Biotechnology by 1.4% during the third quarter. Public Sector Pension Investment Board now owns 194,208 shares of the company’s stock worth $1,455,000 after buying an additional 2,600 shares in the last quarter. Finally, Captrust Financial Advisors bought a new stake in shares of Vir Biotechnology in the third quarter worth $118,000. 65.32% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

VIR has been the subject of several recent analyst reports. Barclays raised their price objective on shares of Vir Biotechnology from $26.00 to $31.00 and gave the stock an “overweight” rating in a report on Friday, February 28th. Morgan Stanley upgraded Vir Biotechnology from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $10.00 to $20.00 in a research note on Thursday, January 9th. Leerink Partners upped their price objective on Vir Biotechnology from $18.00 to $20.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 target price on shares of Vir Biotechnology in a research report on Thursday, February 27th. Finally, HC Wainwright reiterated a “buy” rating and issued a $110.00 price target on shares of Vir Biotechnology in a report on Friday, February 28th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $35.67.

Insider Activity

In other news, Director George A. Scangos sold 10,964 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $9.81, for a total value of $107,556.84. Following the completion of the sale, the director now owns 708,295 shares of the company’s stock, valued at $6,948,373.95. This trade represents a 1.52 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Vicki L. Sato sold 10,960 shares of the company’s stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $12.52, for a total value of $137,219.20. Following the transaction, the director now directly owns 1,312,391 shares in the company, valued at $16,431,135.32. The trade was a 0.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,859 shares of company stock valued at $326,458 over the last three months. Insiders own 15.60% of the company’s stock.

Vir Biotechnology Stock Down 3.3 %

Shares of NASDAQ VIR opened at $6.48 on Tuesday. The firm’s 50-day simple moving average is $8.73 and its 200 day simple moving average is $8.35. The stock has a market cap of $888.69 million, a P/E ratio of -1.65 and a beta of 1.17. Vir Biotechnology, Inc. has a fifty-two week low of $6.25 and a fifty-two week high of $14.45.

Vir Biotechnology (NASDAQ:VIR) last released its earnings results on Wednesday, February 26th. The company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.09. The business had revenue of $12.37 million during the quarter, compared to analyst estimates of $8.14 million. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. On average, sell-side analysts anticipate that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.

Vir Biotechnology Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).